Shanghai Junshi Valuation Multiples

Shanghai Junshi Overview

About Shanghai Junshi

Shanghai Junshi Biosciences Co Ltd is mainly engaged in innovation-driven biopharmaceutical business. The company's main products include teriprizumab injection, Etesevimab, adalimumab injection, and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases, and infectious diseases. The group’s operations are mainly located in the PRC and the United States of America.

Founded

2012

HQ

Employees

2.6K

Website

junshipharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $400M

EBITDA: ($70M)

EV

$6B

Valuation Multiples

Multiples.vc

Start free trial

Shanghai Junshi Financials

Shanghai Junshi reported last 12-month revenue of $400M and negative EBITDA of ($70M).

In the same LTM period, Shanghai Junshi generated $323M in gross profit, ($70M) in EBITDA losses, and had net loss of ($104M).

Shanghai Junshi P&L

In the most recent fiscal year, Shanghai Junshi reported revenue of $286M and EBITDA of ($150M).

Shanghai Junshi expects next 12-month revenue of XXX and NTM EBITDA of XXX

Shanghai Junshi Stock Performance

Shanghai Junshi has current market cap of $6B, and enterprise value of $6B.

Shanghai Junshi's stock price is $5.87.

Shanghai Junshi Valuation Multiples

Shanghai Junshi trades at 15.4x EV/Revenue multiple, and (88.5x) EV/EBITDA.

Shanghai Junshi Financial Valuation Multiples

As of April 18, 2026, Shanghai Junshi has market cap of $6B and EV of $6B.

Equity research analysts estimate Shanghai Junshi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Shanghai Junshi has a P/E ratio of (57.6x).

Shanghai Junshi Margins & Growth Rates

Shanghai Junshi's revenue in the last 12 month grew by 31%.

Shanghai Junshi's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.

Shanghai Junshi's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Shanghai Junshi's rule of X is 86% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Shanghai Junshi Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Shanghai Junshi M&A Activity

Shanghai Junshi acquired XXX companies to date.

Last acquisition by Shanghai Junshi was on XXXXXXXX, XXXXX. Shanghai Junshi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Shanghai Junshi Investment Activity

Shanghai Junshi invested in XXX companies to date.

Shanghai Junshi made its latest investment on XXXXXXXX, XXXXX. Shanghai Junshi invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).